Fig 1: Dasatinib and quercetin (D+Q) treatment ameliorates EAE and reduces senescent microglial phenotypes in middle-aged mice. (A) Clinical course of EAE in middle-aged mice treated with vehicle (black, n = 5) or D+Q (blue, n = 5), starting at symptom onset. Dasatinib (5 mg/kg; HY-10181, MedChemExpress) and Quercetin (50 mg/kg; HY-18085, MedChemExpress) suspended in a 10% DMSO/30% PEG300/10% Tween80/50% water solution, or vehicle solution alone, was administered i.v. into the tail vein. Left: daily mean clinical scores; Middle left: area under the clinical score curve (AUC); Middle right: mean peak clinical scores; Right: survival over time. (B–E) Flow cytometric analysis of immune cells harvested from the spinal cords of vehicle-treated (black) and D+Q-treated (blue) EAE mice on day 18 post-transfer. (B–D) Representative contour plots of infiltrating peripheral immune cells (CD45hi) and microglia (CD11b+ CD45int), gated on all viable CD45+ cells, (B) Ly6G+ neutrophils, gated on CD45hi CD11b+ infiltrating peripheral myeloid cells, (C), and CD4+ T cells, gated on CD45+ CD11b- cells (D). (E) Representative histograms showing CD45.1 expression gated on total CD4+ T cells. The percentage of CD45.1+ donor encephalitogenic T cells is shown. (F) Representative histograms showing expression of CD14 (left) and TREM2 (right) on microglia, gated as in (B) All experiments were performed with female C57BL/6 mice purchased from Charles River. Statistical significance was determined using unpaired 2-tailed Student’s t test. (A) Curves in the left panel were compared using a 2-way ANOVA. Error bars indicate mean ± SEM. *p < 0.05, or as indicated.